Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K7 | O43318 | 5/20 | 0.74 |
| ▸ | MAP2K1 | Q02750 | 4/20 | 0.74 |
| ▸ | BTK | Q06187 | 4/20 | 0.74 |
| ▸ | JAK3 | P52333 | 7/20 | 0.71 |
| ▸ | EGFR | P00533 | 5/20 | 0.71 |
| ▸ | JAK2 | O60674 | 1/20 | 0.71 |
| ▸ | BLK | P51451 | 1/20 | 0.71 |
| ▸ | BMX | P51813 | 1/20 | 0.71 |
| ▸ | SRC | P12931 | 3/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.66 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.66 |
| ▸ | FLT3 | P36888 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30854787 | 1.00 | MAP3K7 (0.74) | MAP3K7MAP2K1BTKJAK3EGFR | |
| SCHEMBL29352639 | 1.00 | MAP3K7 (0.74) | MAP3K7MAP2K1BTKJAK3EGFR | |
| SCHEMBL10127876 | 0.88 | JAK3 (0.80) | BTKJAK3EGFRJAK2BLK | |
| SCHEMBL28980968 | 0.87 | BTK (0.80) | MAP3K7MAP2K1BTKJAK3EGFR | |
| SCHEMBL31684778 | 0.87 | BTK (0.80) | MAP3K7MAP2K1BTKJAK3EGFR | |
| SCHEMBL22604799 | 0.85 | BTK (0.62) | MAP3K7MAP2K1BTKJAK3EGFR | |
| SCHEMBL10127962 | 0.85 | BTK (1.00) | MAP3K7MAP2K1BTKJAK3EGFR | |
| SCHEMBL22604617 | 0.85 | EGFR (0.59) | MAP3K7MAP2K1BTKJAK3EGFR | |
| SCHEMBL14914404 | 0.84 | EGFR (0.70) | MAP3K7MAP2K1BTKJAK3EGFR | |
| SCHEMBL28980965 | 0.83 | MAP3K7 (0.81) | MAP3K7MAP2K1BTKJAK3EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2425830-A1 | Synergistic drug combination for the treatment of cancer | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2012-03-07 | — | — | EP | claimed |
| US-12194002-B2 | Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dibromodulcitol | BROWN DENNIS (US) | 2025-01-14 | — | — | US | disclosed |
| US-20240245634-A1 | PCNA INHIBITORS AND EGFR INHIBITORS FOR CANCER TREATMENT | UNITED STATES GOVERNMENT | 2024-07-25 | — | — | US | disclosed |
| EP-3296905-B1 | METHOD FOR IDENTIFYING NEW MARKERS | ALACRIS THERANOSTICS GMBH (DE) | 2023-11-08 | — | — | EP | disclosed |
| US-20230146638-A1 | Treatment of EGFR-Driven Cancer with Fewer Side Effects | G1 THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20220202792-A1 | METHODS AND COMPOSITIONS FOR TREATING CHRONIC INFLAMMATORY INJURY, METAPLASIA, DYSPLASIA AND CANCERS OF EPITHELIAL TISSUES | UNIVERSITY OF HOUSTON SYSTEM (US) | 2022-06-30 | — | — | US | disclosed |
| US-11147800-B2 | Combinatorial methods to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | RACE ONCOLOGY LTD. (AU) | 2021-10-19 | — | — | US | disclosed |
| US-11135201-B2 | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | RACE ONCOLOGY LTD. (AU) | 2021-10-05 | — | — | US | disclosed |
| CN-112472699-A | Combination methods for improving the therapeutic benefit of bisantrene and derivatives | 种族肿瘤学公司 | 2021-03-12 | — | — | CN | disclosed |
| WO-2020206035-A1 | TREATMENT OF CDK4/6 INHIBITOR RESISTANT NEOPLASTIC DISORDERS | G1 THERAPEUTICS, INC. (US) | 2020-10-08 | — | — | WO | disclosed |
| WO-2015013581-A1 | COMBINATORIAL METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE | UPDATE PHARMA INC. (US) | 2015-01-29 | — | — | WO | disclosed |
| WO-2014179528-A2 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS INCLUDING SUBSTITUTED NAPHTHALIMIDES SUCH AS AMONAFIDE FOR THE TREATMENT OF IMMUNOLOGICAL, METABOLIC, INFECTIOUS, AND BENIGN OR NEOPLASTIC HYPERPROLIFERATIVE DISEASE CONDITIONS | BROWN DENNIS M (US) | 2014-11-06 | — | — | WO | disclosed |
| US-20120094999-A1 | EGFR INHIBITORS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120094999-A1 | EGFR INHIBITORS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120094999-A1 | EGFR INHIBITORS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| EP-2440559-A2 | EGFR INHIBITORS AND METHODS OF TREATING DISORDERS | Dana-Farber Cancer Institute, Inc. (US) | 2012-04-18 | — | — | EP | disclosed |
| WO-2012028334-A2 | MARKER FOR SUNITINIB RESISTANCE FORMATION | MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER FÖRDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2012-03-08 | — | — | WO | disclosed |
| EP-2426213-A1 | Marker for sunitnib resistance formation | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2012-03-07 | — | — | EP | disclosed |
| EP-2425830-A1 | Synergistic drug combination for the treatment of cancer | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2012-03-07 | — | — | EP | disclosed |
| WO-2010129053-A2 | EGFR INHIBITORS AND METHODS OF TREATING DISORDERS | DANA FARBER CANCER INSTITUTE (US) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094999-A1 | EGFR INHIBITORS AND METHODS OF TREATING DISORDERS | EGFR, ERBB2, ERBB4 | MAP3K7 121/4885MAP2K1 155/4885BTK 84/4885 |
| US-11135201-B2 | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | CYP3A43, HCCS, MCL1 | MAP3K7 3752/4885MAP2K1 4428/4885BTK 2508/4885 |
| US-11147800-B2 | Combinatorial methods to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | CYP3A43, CYP11B1, MCL1 | MAP3K7 3687/4885MAP2K1 3229/4885BTK 1276/4885 |
| US-20240245634-A1 | PCNA INHIBITORS AND EGFR INHIBITORS FOR CANCER TREATMENT | PCNA, MKI67, EGFR | MAP3K7 146/4885MAP2K1 71/4885BTK 647/4885 |
| US-20220202792-A1 | METHODS AND COMPOSITIONS FOR TREATING CHRONIC INFLAMMATORY INJURY, METAPLASIA, DYSPLASIA AND CANCERS OF EPITHELIAL TISSUES | FABP2, MUC1, FABP6 | MAP3K7 1668/4885MAP2K1 1460/4885BTK 4536/4885 |
| US-12194002-B2 | Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dibromodulcitol | HEXD, DDOST, PAICS | MAP3K7 3307/4885MAP2K1 3856/4885BTK 2699/4885 |
| US-20230146638-A1 | Treatment of EGFR-Driven Cancer with Fewer Side Effects | EGFR, CDK4, CDK6 | MAP3K7 97/4885MAP2K1 87/4885BTK 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.